ÖZ Amaç: Bu çalışmada, mezenkimal kök hücre (MKH) implantasyonunun metisiline dirençli Stafilokokus epidermidis (MDSE)'in neden olduğu vasküler greft enfeksiyonları üzerindeki etkileri değerlendirildi ve antibiyotik tedavisi ile karşılaştırıldı. Gereç ve yöntemler: Sağlıklı erişkin 56 Wistar sıçanı (yaş, 5 ay üzeri; ağırlık, 300-350 g) sekiz gruba ayrıldı. Grup 1 kontrol grubu, grup 2 enfekte kontrol grubu olarak tanımlandı. Grup 3 ve 4 Dakron grefti uygulanan, MDSE ile enfekte olan, sırasıyla tigesiklin ve MKH tedavisi uygulanan gruplar olarak tanımlandı. Grup 5 ve 6 politetrafloroetilen (PTFE) greft uygulanarak MDSE ile enfekte edildi. Bu gruplara da sırasıyla tigesiklin ve MKH tedavisi uygulandı. Grup 7 ve 8 greft uygulanmadan, MDSE ile enfekte edildi ve sırasıyla bu gruplara da tigesiklin ve MKH tedavisi uygulandı. Greftler ve yumuşak doku örnekleri ameliyattan 13 gün sonra alındı. Greft çevresi dokuda koloni sayımı yapıldı. Tüm numuneler, kök hücre aktivitesini gösteren belirteçler açısından enzime bağlı bağışıklık deneyi (ELISA) ile değerlendirildi. Bulgular: Tedavilerin genel başarısı, kullanılan greftten bağımsız olarak, MDSE rekürrensi olan sıçanların sayısı ile değerlendirildi. Tedavi edilmeyen grup 2, tigesiklin grupları (3, 5 ve 7) ile MKH grupları (4, 6 ve 8) arasındaki farklılık istatistiksel olarak anlamlıydı. Mezenkimal kök hücre ve tigesiklin tedavilerinin başarısı Dakron, PTFE ve greft uygulanmayan gruplarda benzerdi. Dakron gruplarında MDSE enfeksiyonunun hem MKH hem de tigesiklin tedavisine karşı bir direnci vardı. Bu, Dakron greftlerinin enfeksiyona duyarlılığının bir göstergesi olarak kabul edildi. Ancak, grup 2 ve Dakron grupları arasında bakteriyel kolonizasyon açısından anlamlı farklılık yoktu. ELISA sonuçları üç sitokinde anlamlıydı. Sonuç: Mezenkimal kök hücreler, tek başına alternatif bir tedavi seçeneği veya vasküler greft enfeksiyonlarının kontrolü için kombine terapinin bir parçası olarak kabul edilebilir. Anahtar sözcükler: Dakron, mezenkimal kök hücreler, politetrafloroetilen, tigesiklin, vasküler greft enfeksiyonları.
The incidence of vascular injury following extremity trauma varies widely according to geographic location (rural, urban), population (civilian, military), and mechanisms of injury (penetrant, blunt). [1] Complex extremity trauma, involving both arterial and skeletal injuries is a clinical challenge. Orthopedic trauma surgeons are more likely to face this combination of injury than vascular and trauma surgeons since most of the limb arterial injuries are associated with skeletal trauma. [2] Particularly Gustilo-Anderson grade 3C fractures, which are associated with severe soft tissue loss and vascular injury, usually require vascular repair. In these complex injuries, the frequency of deep infections and need for major limb amputations are high and multiple surgeries over long periods of time are often required to obtain healing. [3] Despite all precautions and antibiotic use, death rates due to vascular graft infections (15-75%) [1] and limb amputations (70%) are still high. [4, 5] On the other hand, delay in diagnosis and treatment of vascular injury, particularly when complicated by infection and graft thrombosis, may raise the rates of extremity amputations. [6] Prosthetic vascular graft infections occur in up to 6% of patients having bypass distal to inguinal level at the lower extremity. [4] Against alternative treatment approaches as in situ graft replacement [7] and graft retention with thorough debridement, [8] removal of the graft followed by extraanatomic bypass revascularization is the traditional treatment method for vascular graft infections. Methicillin-resistant Staphylococcus epidermidis (MRSE) is the common cause of these infections, [9, 10] which usually does not respond to antibiotherapy, requiring graft excision. [11] Mesenchymal stem cells (MSCs) have immunomodulatory and anti-inflammatory effect achieved by change in T helper subtypes, regulation of the activity of macrophages and changing proliferation, differentiation and immunsecretion characteristics of B cells. [12, 13] They also show direct antibacterial effect achieved by secretion of antibacterial peptides and augmentation of phagocytosis. [14] The efficacy of treatment with allogeneic and autogenic MSC transplantation has been demonstrated on myocardial infarction, [15] diabetes, [16] graft versus host disease, [17] acute infectious lung injury, [18] sepsis and organ dysfunction, [19] staphylococcus toxic shock syndrome, [20] and peritonitis. [21] Thus, the anti-infectious effect of MSCs may be studied on other clinically resistive forms of infection.
In this study, we hypothesize that MSCs can be an effective treatment option in vascular graft infections due to their direct anti-microbial and immunomodulating effects in patients who need treatment of vascular graft infections, particularly who are unable to use antibiotics or require dose adjustment due to the side effects. Thus, in this study, we aimed to evaluate the effects of MSCs implantation on vascular graft infections caused by MRSE and compare with antibiotic treatment.
MATERIALS AND METHODS
This study was conducted at Kırıkkale University Medical Faculty between 10 August 2016 and 21 December 2017 with the approval of the Local Animal Experiments Ethics Committee dated 10.06.2016 and numbered 16/61. All animals were maintained in accordance with the principles of animal care developed by the National Academy of Sciences (Guide for the Care and Use of Laboratory Animals). We conducted a power analysis to determine the size of the study group prior to the ethics committee application. During the entire study, rats were examined under veterinary supervision, fed a standard diet without water deprivation, at 22±1.9°C room temperature and 52±6% relative humidity, in the Experimental Animal Research Laboratory. [22] Healthy adult 56 Wistar rats (age, over 5 months; weighing, 300-350 g) were randomly divided into eight groups, each group consisting of seven rats. Group 1 was defined as the control group. No graft was implanted in these rats. They were uncontaminated and did not receive antibiotic treatment or MSCs implantation. Group 2 was defined as the infected control group. These rats were not grafted with Dacron or polytetrafluoroethylene (PTFE). They were locally infected with MRSE and not treated with antibiotics or MSCs. In group 3, Dacron graft was implanted into rats, they were locally infected with MRSE and treated with intraperitoneal tigecycline 10 mg/kg for 10 days twice daily. Dacron grafting was also performed for group 4 rats which were again locally infected with MRSE and treated with single dose local implantation of 2¥10 6 MSCs. Group 5 rats had PTFE graft implantation infected with MRSE and treated with intraperitoneal tigecycline 10 mg/kg for 10 days twice daily. Group 6 rats also received PTFE grafting, locally infected with MRSE and treated with single dose local administration of 2¥10 6 MSCs. Group 7 rats were the non-grafted, infected rats with MRSE and they received intraperitoneal tigecycline 10 mg/kg for 10 days twice daily. Group 8 rats were also non-grafted, locally infected with MRSE and treated with single dose local administration of 2¥10 6 MSCs.
Methicillin-resistant Staphylococcus epidermidis was isolated from a 72-year-old male patient with osteomyelitis in 2016. Samples from the infected area were obtained and taken for routine bacteriological studies at the Department of Microbiology of the Veterinary Medicine at Kırıkkale University. Clinical isoforms were determined by gram staining, catalase reaction, tube coagulase test and API-Staph test (bioMérieux, Lyon, France). Methicillin susceptibility was determined using the Kirby Bauer Disk Diffusion method. [23] Susceptibility of MRSE strains to antimicrobial effect of tigecycline was determined according to Clinical and Laboratory Standards Institute procedures and Kirby Bauer Disk Diffusion method. Tigecycline (TYGACIL, Pfizer ® , NY, USA) dose (10 mg/kg) was adjusted according to the dosage regimen found effective in animal studies. [24] Diagnosis of infection was confirmed by gram staining and culture of samples obtained in group 2 infected control group of rats. Organisms were quantified as the number of colony-forming units (CFUs) per container.
Fast thaw technique was used [25] where cells were thawed by transferring warmed media to a frozen tube quickly and transferring to a reaction tube. The tissue was rinsed to remove blood cells and then mechanically separated into small pieces that were no longer than a few millimeters. [26] Rat adipose cells were taken from a rat and used to prepare Rat MSCs at Yildirim Beyazit University Stem Cell Laboratory. Mesenchymal stem cells were isolated from rat inguinal area and subcutaneous flank adipose tissue. Explant culture technique was used to isolate the MSCs. Explant culture is one of the earliest techniques of cell isolation and in vitro cell culture. Small piece tissues are placed in culture dishes and cells migrate out to adhere to the culture surface; no enzyme is used in this technique. [27, 28] Cell counts and survival were performed using the Countess ® Automated Cell Counter (Thermo Fisher Scientific, Waltham, USA).
All animals were sedated intramuscularly (0.75 mL/kg) with 2:1 mixed ketamine hydrochloride (100 mg/mL; Pfizer, Luleburgaz, Turkey) and xylazine hydrochloride (20 mg/mL; Bayer AG, Leverkusen, Germany). The fur on the back of each rat was shaved and disinfected with a 10% povidone-iodine solution. A subcutaneous pocket was made with 1 cm cuts in the middle of the back (Figure 1 ). [29] 1 cm 2 , woven, gelatin impregnated Dacron grafts (Gelweave, Sulzer Vascutek Ltd., Scotland, United Kingdom) and 1 cm 2 PTFE grafts (Gore-Tex; W.L. Gore & Associates Inc., Newark, USA) were used. Twenty-four hours later, sterile saline solution (1 mL) equal to MRSE at 2¥10 6 CFU per mL was inoculated onto the surface of the grafts with a tuberculin syringe. After 48 hours, sterile saline solution (1 mL) equivalent to MRSE at 2¥10 6 CFU per mL was inoculated onto the surfaces of groups 2, 7 and 8 grafts with a tuberculin syringe. Animals were individually housed in cages and checked daily for wound healing. All grafts were implanted on the first day. On the second day, the infection agent (MRSE) was injected into the graft site. The anti-infective therapy was started on the third day. As advised by Goessens et al., [24] 10 days after the anti-infective treatment, all grafts were taken under sterile conditions on the 13 th day of graft implantation. After this process, all animals were sacrificed.
Mesenchymal stem cells express various growth factors (e.g., vascular endothelial growth factor [VEGF]; hepatocyte growth factor; insulin-like growth factor-1; fibroblast growth factor [FGF]; keratinocyte growth factor; transforming growth factor-beta [TGF-b]) and anti-inflammatory cytokines (e.g., prostaglandin E2). [30] Proinflammatory cytokines, particularly interleukin 1 (IL-1) and tumor necrosis factor alpha (TNF-b) upregulated during the inflammatory process. [31] The standard enzyme-linked immunosorbent assay method was used for analyzing quantification of FGF, TGF-b1, IL-1 alpha (IL-1a), VEGF, TNF-a, plateletderived growth factor (PDGF) and caspase 3 (CASP3) cytokines [32] to evaluate the effect of MSCs in the infected tissue samples.
Statistical analysis
Statistical analyses were performed using the IBM SPSS version 24.0 (IBM Corp., Armonk, NY, USA) software. The variables were investigated using visual (histograms, probability plots) and analytical methods (Kolmogorov-Smirnov/Shapiro-Wilk's test) to determine whether they are normally distributed. Descriptive statistics were presented as median (first quantile-third quantile). Normally distributed data were analyzed by one-way analysis of variance (ANOVA) followed by Kruskal Wallis. Data were shown as mean±standard deviation of absolute number. The Mann-Whitney U test was used to compare the success of treatment between the groups. Bonferroni correction was used to adjust for multiple comparisons. The chi-square test or Fisher's exact test, where appropriate, was used to compare groups in terms of the number of rats in which reproduction was detected. A two tailed p value less than 0.05 was considered to show a statistically significant result.
RESULTS
There was no animal that died for any reason during the study. In addition, local effects, anorexia, nausea, vomiting, diarrhea or behavioral disturbances were not observed in any group.
There was a significant difference in terms of bacterial colonization between group 1 (control group) and group 2 (infected control) (p=0.004). No treatment was applied to groups 1 and 2. In groups 3 and 4, a small number of bacterial colonization was observed irrespective of treatment. However, the difference between groups 3 and 4 was not statistically significant. There was no bacterial recurrence occurred in groups 5, 6, 7 and 8. Bacterial colonization was not observed in MSCs-treated groups 6 and 8, whereas in group 4, another MSCstreated group, reproductive activity was detected. In groups 5 and 7 treated with tigecycline, there was no bacterial colonization, whereas, in group 3, which was also treated with tigecycline, bacterial colonization was found to be minimal. The grafts placed in the tissues, the cultivated agents and the quantitative culture results are given in Table I .
The numbers of colonization according to grafts and treatments are given in Table II as mean, median 25% and median 75%. There was a statistically significant difference between groups 1 and 2 in terms of colony numbers (p<0.001). Both successes of groups 3 and 4 were statistically significant when compared with group 2 (p<0.001, p<0.001). The treatment success was similar in groups 3 and 4 (p=0.004). There was no statistically significant difference in terms of treatment success between the PTFE grafted groups (p=0.91). Groups 3, 5 and 7, treated with tigecycline, were compared in terms of colony counts. In groups 5 and 7, tigecycline treatment was more successful than group 3 (p<0.001). Groups 4, 6 and 8, treated with MSCs, were evaluated in terms of colony counts. Mesenchymal stem cell treatment was more successful in groups 6 and 8 than in group 4 (p<0.001). Treatment successes in PTFE groups and non-grafted groups were similar (p>0.05). The overall success of the treatments was assessed by the number of rats with MRSE recurrence, regardless of graft use. The difference between untreated group 2 and tigecycline groups and MSCs groups was statistically significant (p=0.016, p=0.016). There was no significant difference between group 2 and Dacron groups in terms of reproductive status. The difference between Dacron groups and PTFE groups and non-grafted groups was significant (p=0.047, p=0.047). The results were similar in PTFE groups and non-grafted groups 7 and 8 (p>0.05).
Enzyme-linked immunosorbent assay results of all groups of FGF, TGF-b1, IL-1a, VEGF, TNF-a, PDGF and CASP3 are shown in Table III . Kolmogorov-Smirnov test showed that all variables had a normal distribution. Descriptive statistical analysis results are given in Table 3 . Because the variances were homogeneous, multiple comparisons between groups were performed using the lysergic acid diethylamide (LSD) method (Tables IV, V). Variables that differ between groups are given in Table 5 . ANOVA analysis was performed because the variables had a normal distribution, and significant differences were found between the groups in the IL-1a, VEGF and CASP3 variables. Multiple post-hoc tests were performed to identify the different groups (Table VI) .
DISCUSSION
The results of this study can be summarized in two statements. Firstly, it was shown that both MSCs implantation and tigecycline treatment are effective against MRSE at vascular graft site and soft tissue infections. Secondly, these two anti-infective treatments are successful in the treatment of MRSE infections at PTFE grafted sites where they fail to control and treat bacterial colonization at Dacron graft site infections.
Vascular graft infection is a rare complication after graft implantation but is associated with a high mortality rate (up to 75%) and a high rate of major amputation (as high as 70%). [4, 33, 34] For particularly open lower extremity injury and fractures, both late diagnosis [6] and late revascularization due to graft problems including thrombosis and infections increase the amputation rates. Thus, for these clinical scenarios, more aggressive and rapid treatment has to be developed. Staphylococcus aureus, Staphylococcus epidermidis and gram-negative Escherichia coli (E. coli) are the most common pathogens isolated in vascular graft infections. The development of resistance and reduction of susceptibility [35] to methicillin at the beginning and vancomycin later by the staphylococci gave rise to investigations for alternative treatment options for vascular graft infections. [10] Tigecycline, the first generation of glycycline antibiotics, is one of the choices of treatment in infections caused by methicillin-resistant Staphylococcus aureus (MRSA), MRSE, and vancomycin-resistant enterococcus infections. [36, 37] Thus, it is one of the alternative antimicrobial treatments for vascular graft infections resistant to methicillin or vancomycin. Although it is out of the aim of this study, we demonstrated the effective antimicrobial efficacy of tigecycline for both PTFE grafted and non-grafted MRSE infections. However, there are some concerns about tigecycline treatment. A meta-analysis performed by Shen et al. [38] has reported lower cure rates with tigecycline according to data extracted from 14 studies evaluating totally 5,663 patients. In the same meta-analysis, although not statistically significant, reported microbiological treatment success was numerically lower than compared treatment regimens including MRSA, MRSE, E. coli, and Klebsiella. The most important and remarkable negative finding of tigecycline treatment is the significantly higher number of side effects particularly in the digestive, hematopoietic and lymphatic systems. [37] Also, numerically higher mortality is observed although statistically not significant. [37, 38] Mesenchymal stem cells modulate the activity of macrophages. These effects have been demonstrated in ex-vivo demonstration by macrophages induced by Toll-like receptor ligands such as lipopolysaccharide, zymosan or polyinosinic-polycytidylic acid. [39] When macrophages are stimulated with bacterial or viral agents, they secrete inflammatory factors such as TNF-a, IL-1, and IL-6. [13] In our study, successful results with MSCs similar to tigecycline treatment were obtained in terms of bacterial colonization in both PTFE grafted and non-grafted infection sites. The antibacterial properties of MSCs are related with their immunomodulating and direct antibacterial effect on the infectious agent. [13, 15, 19, 40] As immunomodulators, MSCs initiate a shift in the ratio of T helper cells through T helper 2 anti-inflammatory subtype and increase differentiation of naive T cells to regulatory phenotype. [13] They also modulate the activity of macrophages. The direct anti-infectious effects are provided by secretion of antibacterial peptides and intensification of phagocytosis. [14, 19] The increase in IL-1 and particularly its a subtype may be responsible from anti-infective properties of MSCs because it is well documented that IL-1a promotes the release of chemokines and adhesion molecules by inducing endothelial cells. [41, 42] Thus, it provides white blood cells to reach the infected area with chemotaxis and augments inflammation. In our study, MSCs implantation increased IL-1a levels, particularly in the PTFE groups more than other groups. Bartosh et al. [43] also demonstrated that MSCs triggered IL-1 signaling and secretion of inflammation and immune modulators. In the literature, there are studies supporting these effects of experimental MSCs, many of which were performed on sepsis models. [19] Devaney et al. [18] demonstrated in a mouse model of E. coli-induced pneumonia a lesser intensity of lung damage, lower bacterial load, and higher intensity of phagocytosis following the intratracheal administration of MSCs. Also, Pedrazza et al. [21] showed a significant decrease in mortality in the group that received MSCs compared to the control group which was a mouse model of sepsis induced by the administration of E. coli into the peritoneal cavity. These reported results are parallel to those obtained for vascular graft site infections in our study.
Another remarkable finding of this study is the resistance of MRSE infections to both MSCs implantation and tigecycline treatment. This significant difference in Dacron grafted groups can be considered to be indicative of the susceptibility of the Dacron grafts to infection. Schmitt et al. [44] demonstrated that bacterial adherence to knitted Dacron grafts is more than adherence to PTFE grafts, which is related to the surface area, porosity, and chemical structure. The difference in these structural characteristics creates the difference in bacterial affinity between the PTFE and Dacron graft materials. In addition, they underlined that PTFE is more hydrophobic than Dacron resulting in forming a lesser number of bonds with hydrophobic cell walls. This predisposition of Dacron graft to infection needs to be demonstrated by further histopathological investigations. However, we advise preferring PTFE grafts for vascular grafting particularly for repairing vascular injury at the open wound or fracture sites.
This experimental study has some limitations. Our in vivo model used a direct method of MRSE colonization on the graft. Thus, grafts are not comparable to the animal model for applying into a blood vessel. The antibiotics were administered intraperitoneally instead of intravenously and antibiotic binding to the grafts was not assessed. Additionally, the effect of the combination of antibiotics with MSCs implantation was not demonstrated in a group. All the limitations mentioned above are inherent to experimental studies; therefore, further human studies are needed. MSCs practice is not yet cheaper than costly antibiotics; however, we may assume that the cost will decrease as this practice becomes more widespread.
In conclusion, MSCs can be a good alternative treatment option as single or combination therapy for vascular graft infections. They can be an effective part of treatment for patients with organ failures where sensitive dose adjustment for antibiotics is required, for patients with a high risk of graft infection due to contamination of vascular injury site, and also for those under 18 years of age for whom many antibiotics cannot be used due to side effects. In addition, for potential resistance of MRSE to tigecycline in near future, MSC therapy alone or combination with antibiotics may be a good alternative treatment choice. Moreover, MSC therapy may slow down and delay the time course of resistance development to tigecycline therapy. As we mentioned, MSC culture techniques are not cheaper yet; however, we believe that MSCs will be cultured at lower-cost techniques in local laboratories in near future. We need further animal and human studies to find out the efficacy of MSC treatment in infected vascular grafts.
